维奈克拉联合儿童方案治疗青少年及成人Ph阴性急性淋巴细胞白血病
这项前瞻性2期研究纳入167例14-60岁初诊Ph阴性急性淋巴细胞白血病患者,接受维奈克拉联合儿童方案化疗。完全缓解率91.0%,其中73.0%达流式MRD阴性,达到主要终点;中位随访19.3个月,2年总生存率和无病生存率分别为78.5%和76.7%,安全性可控。
要点
- 维奈克拉联合儿童方案化疗在初诊Ph阴性ALL中完全缓解率达91.0%。
- 73.0%的缓解者诱导后达多参数流式MRD阴性,达到主要终点。
- 2年总生存率和无病生存率分别为78.5%和76.7%,安全性可控。
核心结论
- 维奈克拉联合儿童方案化疗可显著改善初诊Ph阴性ALL的MRD反应和生存结局,安全性可控。
研究设计与样本
- 前瞻性2期研究,纳入167例14-60岁初诊Ph阴性急性淋巴细胞白血病患者。
- 治疗方案为维奈克拉联合儿童方案化疗,主要终点为诱导后多参数流式细胞术MRD阴性率。
主要发现
- 完全缓解率为91.0%,73.0%的缓解者达MFC-MRD阴性,达到主要终点。
- 中位随访19.3个月,中位总生存和无病生存未达到,估计2年生存率分别为78.5%和76.7%。
- 倾向评分匹配分析证实生存优于历史单纯化疗对照。
- ≥3级不良事件主要为血液学毒性和感染,发生率与历史队列相当。
关键数值与推荐
- 完全缓解率91.0%,MFC-MRD阴性率73.0%(缓解者中)。
- 估计2年总生存率78.5%,2年无病生存率76.7%。
- 中位随访19.3个月,中位总生存和无病生存未达到。
临床怎么用
- 对14-60岁初诊Ph阴性ALL患者,可考虑维奈克拉联合儿童方案化疗以提高MRD阴性和生存。
- 治疗中需关注血液学毒性和感染等≥3级不良事件。
局限性
- 为单臂2期研究,与历史对照的比较采用倾向评分匹配分析。
- 中位随访19.3个月,长期生存数据尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The B-cell lymphoma 2 inhibitor venetoclax has shown promise in acute lymphoblastic leukemia (ALL), but its role in first-line therapy for newly diagnosed (ND) Philadelphia chromosome-negative (Ph-) ALL is undefined. In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph- ALL received venetoclax combined with pediatric-inspired chemotherapy. The primary end point was the rate of measurable residual disease (MRD) negativity by multiparameter flow cytometry (MFC) after induction. The complete remission rate was 91.0%, and 73.0% of responders achieved MFC-MRD negativity, meeting the primary end point. After a median follow-up of 19.3 months, median overall and disease-free survival were not reached; estimated 2-year survival rates were 78.5% and 76.7%, respectively. Propensity score-matched analysis confirmed superior survival compared with historical chemotherapy-only controls. Grade ≥3 adverse events were primarily hematologic toxicities and infections, with an incidence comparable with that of the historical cohort. These results demonstrate that adding venetoclax to pediatric-inspired chemotherapy significantly improves MRD response and survival outcomes in newly diagnosed (ND) Ph- ALL, with a manageable safety profile. This trial was registered at www.clinicaltrials.gov as #NCT05660473.
引用
- Gong X, Liu Y, Fang Q, et al. Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia. Blood. 2026. PMID: 42166560. doi:10.1182/blood.2026033577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。